Patients’ experience sharing on using maribavi/Yitazhi

Maribavir offers a new treatment pathway for patients with post-transplant resistant or recurrent cytomegalovirus (CMV) infection, particularly those who have failed to respond to ganciclovir, valganciclovir, cidofovir or foscarnet. According to overseas patient communities and clinical case reports, patients’ experience after using maribavir is mainly reflected in drug tolerance and improvement in quality of life. Many patients reported that compared with the traditional anti-CMV drugs previously used, maribavir has obvious advantages in reducing side effects, especially the problems of nephrotoxicity and bone marrow suppression.

In terms of dose management, patients usually take the drug twice daily, and doctors will adjust the dose based on viral load and clinical response. Some patients mentioned taste changes during early use, but most adapted to it after a few weeks and did not affect their daily lives. Clinicians recommend that patients maintain regular reexamination during use and monitor viral load and blood indicators. This not only helps evaluate the efficacy, but also detects potential adverse reactions in a timely manner.

From a psychological perspective, drug resistanceCMV patients are often accompanied by worries about recurrence. The experience of using maribavi shows that the drug is effective in controlling viral replication, giving patients a certain sense of psychological security and improving their quality of life. The patient community also shared their experience in rationally arranging drug taking time and using it in conjunction with other immunosuppressants, emphasizing the importance of following medical advice and regular monitoring.

Overall, as a third-generation CMV therapeutic drug, maribavivir, combined with Takeda's R&D support, clinical safety and patient experience, provides a practical treatment option for drug-resistant CMV infections. It not only meets clinical needs in terms of efficacy, but also shows good performance in terms of long-term use and patient quality of life, providing an important reference for future clinical promotion and patient management.

Reference materials:https://go.drugbank.com/drugs/DB06234